Clinical Enterprise
Andrew Geller MS, MB(ASCP) is an accomplished professional in the field of molecular diagnostics with significant experience in research and development. Currently serving as Vice President of Research and Development at Clinical Enterprise, Andrew Geller has led the innovation and strategic development of numerous molecular tests, overseeing major projects such as single cell RNA sequencing and NGS-based proteomics. Previous roles include Director of Research and Development, where Andrew Geller provided scientific leadership and successfully launched new molecular tests, including a RT-PCR assay for SARS-CoV-2. Their educational background includes a Master of Science in Biochemical and Molecular Nutrition from The Friedman School of Nutrition Science and Policy at Tufts University and a Bachelor of Science in Biology from Union College.
This person is not in any teams
Clinical Enterprise
Engineered for integration, powered for collaboration Eurofins Clinical Enterprise is uniquely positioned to deliver hyper-accelerated data, along with rapid, robust, and reliable testing that can be easily replicated, providing you with the research excellence you need at highly competitive prices. Our CLIA-certified, CAP-accredited, 20,000 square foot laboratory includes a powerful fleet of instruments and exceptionally credentialed scientific team. We offer: ✔️ Clinical-grade laboratory developed testing services ✔️ Numerous research-use only options ✔️ Diverse genetic analysis platforms ✔️ Proprietary client integration tools that maximize efficiency ✔️ Robust client messaging capacity Take your first step toward research success and find your reference laboratory partner today.